increased heart rate on semaglutide elevated Presented at #ACC24: Among patients with obesity-related heart failure with preserved elevated heart rate semaglutide Retatrutide

For diabetes providers, it signals a shift toward integrated, chronic management models that tackle obesity head-on not as a side issue, but as a core component of care

As access becomes more difficult, were seeing the rise of compounded products, black-market peptides, and unregulated supplements that claim to mimic GLP-1s

Studies have indicated that these medications can help reduce cardiovascular risk factors, such as high blood pressure and cholesterol levels, which is a major advantage for patients with obesity

Conclusions Among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both, the use of oral semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than placebo, without an increase in the incidence of serious adverse events